Third degree AV block medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:
A patient with inferior wall [[myocardial infarction]] and distal high grade complete heart block with a heart rate of more than 60 beats per minute is at immediate danger of [[asystole]] and requires an immediate placement of permanent [[pacemaker]] compared to a patient with inferior myocardial infarction and complete block at the level of AV node with a heart rate of 35-40 beats per minute.
A patient with inferior wall [[myocardial infarction]] and distal high grade complete heart block with a heart rate of more than 60 beats per minute is at immediate danger of [[asystole]] and requires an immediate placement of permanent [[pacemaker]] compared to a patient with inferior myocardial infarction and complete block at the level of AV node with a heart rate of 35-40 beats per minute.


Correction of reversible causes of the block such as [[ischemia]], medications ([[beta-blocker]]s, [[calcium channel blocker]]s, [[antiarrhythmics]], and [[digoxin]]), and vagotonic conditions should be considered. Treatment may also include medicines to control [[blood pressure]] and [[atrial fibrillation]], as well as lifestyle and dietary changes to reduce [[risk factor]]s associated with [[heart attack]] and [[stroke]]. A new third degree AV block is an emergency. Treatment in emergency situations are [[atropine]] and an [[external pacer]].   
The management of third-degree AV block depends on the severity of signs, symptoms, and the underlying cause. In symptomatic patients and with hemodynamic distress, pharmacological therapy should be initiated immediately to increase heart rate and cardiac output. Most of the patients who do not respond to pharmacologic therapy require a temporary pacemaker. After stabilizing the patients, assessment and treatment of potentially reversible causes should be done. Some patients without reversible cause or unidentified etiology require a permanent pacemaker<ref>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2019 Aug 20;74(7):1016-1018]. ''J Am Coll Cardiol''. 2019;74(7):e51‐e156. doi:10.1016/j.jacc.2018.10.044</ref>. A new third degree AV block is an emergency. Treatment in emergency situations are [[atropine]] and an [[external pacer]].   


===Acute Pharmacotherapy===
===Acute Pharmacotherapy===

Revision as of 20:21, 23 May 2020

Third degree AV block Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Third degree AV block from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Third degree AV block medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Third degree AV block medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Third degree AV block medical therapy

CDC on Third degree AV block medical therapy

Third degree AV block medical therapy in the news

Blogs on Third degree AV block medical therapy

Directions to Hospitals Treating Third degree AV block

Risk calculators and risk factors for Third degree AV block medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Raviteja Guddeti, M.B.B.S. [3]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Medical Therapy

A patient with inferior wall myocardial infarction and distal high grade complete heart block with a heart rate of more than 60 beats per minute is at immediate danger of asystole and requires an immediate placement of permanent pacemaker compared to a patient with inferior myocardial infarction and complete block at the level of AV node with a heart rate of 35-40 beats per minute.

The management of third-degree AV block depends on the severity of signs, symptoms, and the underlying cause. In symptomatic patients and with hemodynamic distress, pharmacological therapy should be initiated immediately to increase heart rate and cardiac output. Most of the patients who do not respond to pharmacologic therapy require a temporary pacemaker. After stabilizing the patients, assessment and treatment of potentially reversible causes should be done. Some patients without reversible cause or unidentified etiology require a permanent pacemaker[1]. A new third degree AV block is an emergency. Treatment in emergency situations are atropine and an external pacer.

Acute Pharmacotherapy

Atropine

Atropine can partially or completely restore conduction through the AV node when the cause for complete heart block is acute myocardial infarction (ischemia of the AV node). Atropine, in this setting, reverses the reduced conduction across the AV node (which is due to increased vagal tone). But caution is advised in such cases as the resulting vagolysis leads to unopposed sympathetic activity. This increased sympathetic activity causes ventricular irritability and can progress to fatal ventricular arrhythmias.

Use of atropine in situations where the block is at the level of His bundle can lead to increased atrial rate and a greater degree of heart block with reduced ventricular rate.

Atropine is unsuccessful in wide complex bradyarrhythmias (block below the AV node). It is also not helpful in a denervated heart, like in patients who have undergone a cardiac transplant procedure.

Isoproterenol

Isoproterenol may help accelerate a ventricular escape rhythm and restore conduction with distal level of block but the probability for efficacy is low. Active ischemic heart disease is an absolute contraindication for the use of isoproterenol.

DigiFab

DigiFab is an immunoglobulin fragment used in the treatment of digitalis overdose. It has specific high affinity for digoxin and digitoxin molecules and removes them from the tissues. The dose of DigiFab depends on the concentration of digoxin in the body.

Number of vials of DigiFab = (Digoxin concentration)×(Patient's weight)÷100

Transcutaneous Pacing

Transcutaneous pacing is the treatment of choice in symptomatic patients. Any patient with complete heart block associated with frequent pauses, inadequate ventricular escape rhythm and block below the AV node should be paced temporarily using a transcutaneous pacemaker to attain stability. Disadvantages of using a transcutaneous pacemaker are:

  • It is not a reliable method and
  • It is extremely uncomfortable for the patient.

If perfect capture is not obtained with a transcutaneous pacer, attempt should be made to pace the patient temporarily using transvenous pacing method. This method is employed in the emergency room for all patients with hemodynamic instability and in whom perfect capture cannot be obtained with a transcutaneous pacer.

Contraindicated medications

Third degree AV block(except in patients with a functioning artificial pacemaker) is considered an absolute contraindication to the use of the following medications:

References

  1. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2019 Aug 20;74(7):1016-1018]. J Am Coll Cardiol. 2019;74(7):e51‐e156. doi:10.1016/j.jacc.2018.10.044

Template:WikiDoc Sources